1. Pfizer Inc. projects the following cash flows for the upcoming fiscal year ending December 31, 2024:
   • Expected Net Sales: $600,000,000
   • Expected Cost of Goods Sold: $300,000,000
   • Depreciation Expense: $80,000,000
   • Operating Expenses: $120,000,000
   • Interest Expense: $30,000,000
   • Income Tax Expense: $150,000,000
   • Capital Expenditures: $200,000,000
   • Expected Cash Flows from Financing Activities: $250,000,000

a. Forecast Pfizer Inc.'s Operating Cash Flow (OCF) and Free Cash Flow (FCF) for the fiscal year. b. Analyze Pfizer Inc.'s projected capital expenditures and their impact on future cash flows. c. Discuss how Pfizer Inc.'s financing activities contribute to its overall liquidity and financial stability. d. Evaluate the projected income tax expense and its influence on Pfizer Inc.'s profitability. e. Recommend strategies for Pfizer Inc. to manage its cash flows effectively amidst high capital expenditures.